JCO Global Oncology最新文献

{"title":"First Decade of the National Cancer Institute's Affordable Cancer Technologies Program: Accelerating Translational Technology Research and Development for Cancer Globally.","authors":"Paul C Pearlman, Rao Divi, Rebecca Huppi, Elise Garton, Srivatsan Kidambi, Pushpa Tandon, Miguel Ossandon, Ophira Ginsburg, Satish Gopal","doi":"10.1200/GO-25-00200","DOIUrl":"10.1200/GO-25-00200","url":null,"abstract":"<p><p>Since 2014, the National Cancer Institute Affordable Cancer Technologies (ACTs) program has supported a broad research portfolio focused on the development and validation of new technologies for global cancer control. ACTs projects are conducted by international teams composed of investigators from the United States and low- and middle-income countries, spurring important contextually relevant innovations. During its first decade, the ACTs program ushered in new technology platforms, led to commercialized products, and affected health policies and programs worldwide including in the United States. It has allowed a new generation of investigators working across disciplines and national borders to pursue novel technological solutions and leverage new analytic methods to advance human health. This commentary lays out the scope and accomplishments of the ACTs program to date while considering possible future research directions.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500200"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison Between Acute Leukemia Screening Tube and Lineage-Specific Panels for the Diagnosis of Acute Leukemia in Kenya.","authors":"Douglas I Munga, Nancy A Okinda, Geoffrey A Omuse, Elizabeth M Kagotho","doi":"10.1200/GO-25-00069","DOIUrl":"https://doi.org/10.1200/GO-25-00069","url":null,"abstract":"<p><strong>Purpose: </strong>Acute leukemia is a group of hematologic malignancies categorized according to the immature cells that proliferate and replace the normal bone marrow. Flow cytometry has emerged as a cornerstone in the diagnosis of hematologic malignancies. Staged analysis with a screening tube containing specific lineage markers determines the need for subsequent testing if there is an abnormal population (blasts). The specific lineage panels to be analyzed are determined depending on the positive markers in the screening tube. This study aimed to determine the agreement of diagnosis using the acute leukemia screening tube (ALST) and the lineage-specific panel.</p><p><strong>Methods: </strong>This was an analytical cross-sectional study performed at the Aga Khan University Hospital, Nairobi. It included 256 cases diagnosed as acute leukemia. The diagnosis after the screening tube was compared with the final diagnosis from the lineage-specific panels, and Cohen's Kappa was used to determine the level of agreement.</p><p><strong>Results: </strong>Of the 256 cases, the overall agreement was 94%, with 14 cases being discordant. Myeloperoxidase interpretation in the screening tube accounted for 64% (9 of 14) of the discrepant results.</p><p><strong>Conclusion: </strong>The study demonstrated that the ALST is almost as good as lineage-specific panels in the diagnosis and classification of acute leukemias. The screening tube can be an added diagnostic tool to complement morphology in resource-limited centers with the capacity to interpret flow cytometry analysis.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500069"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Who Reconstitutes the Chemotherapy? The Educational and Practice Needs of Oncology Pharmacists in West Africa: A Call for Multidisciplinary Team Approach in Oncology Care.","authors":"Runcie C W Chidebe, Ramatu M Alabelewe, Krishna Prasad Sapkota, Darlingtina K Esiaka, Candidus C Nwakasi, Gloria C Okwu, Jacinta Emejulu, Adamu A Umar, Ndifreke Okwuegbunam, Funsho David, Toyosi Adepoju, Agha A Agha, Ejike S Ugwu, Simeon C Aruah, Richard Mshelia, Rob Duncombe, Noel N Wannang, Peace C Babalola, R Donald Harvey, Cindy O'Bryant, Folakemi T Odedina","doi":"10.1200/GO-25-00021","DOIUrl":"https://doi.org/10.1200/GO-25-00021","url":null,"abstract":"<p><strong>Purpose: </strong>Oncology pharmacists (OPs) play a crucial role in cancer care, treatment, survivorship, and multidisciplinary teams (MDTs). OPs have specialized training in designing, administering, monitoring, and modifying oncology chemotherapy; managing adverse events; and evaluating clinical trials and investigational drugs. Yet, the state of OP has remained largely unknown in the clinical oncology workforce of the West African region. Therefore, this study aimed to understand who reconstitutes chemotherapy and to explain the OP educational and practice needs, challenges, and solutions in Nigeria.</p><p><strong>Materials and methods: </strong>Using a concurrent embedded mixed method design, 35 OPs completed a questionnaire, and 12 others responded to a semistructured interview. The data were then subjected to inductive thematic and descriptive analyses.</p><p><strong>Results: </strong>The findings showed that 54% of the OPs were responsible for chemotherapy reconstitution, and only 60% of the oncology centers had a biosafety cabinet. 91% of OPs were practicing; however, only 54% were trained in OP, and none of the OPs were board-certified. Most of the OPs spent time weekly on reconstitution, administrative duties, teaching, and training; only 3% spent on oncology clinical trials and conferences and 8% on noninterventional research. We identified four themes: (1) Some OPs are not reconstituting chemotherapy: A Call for MDT, (2) For OP, No Training is Enough, (3) Board Certification will give OPs Recognition, and (4) Introduction of OP Course in Universities.</p><p><strong>Conclusion: </strong>To improve patient treatment outcomes, training on chemotherapy reconstitution should be prioritized, integration of OPs into MDTs, and the safe handling of chemotherapy in centers should be mandated in the region. The West African Postgraduate College of Pharmacists should be supported in expanding its curriculum and introducing OP fellowships.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500021"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Germline Variants in Advanced Renal Cell Carcinoma in North India.","authors":"Chitrakshi Nagpal, Mohit Kumar Divakar, Hemavathi Baskarane, Ghazal Tansir, Rishabh Jain, Aparna Sharma, Ranjit Kumar Sahoo, Sameer Bakhshi, Ishaan Gupta, Shilpi Minocha, Saran Kumar, Pranay Tanwar, Brusabhanu Nayak, Rishi Nayyar, Sridhar P, Seema Kaushal, Sanjay Ojha, Parnika Nangla, Kunhi Parambath Haresh, Amlesh Seth, Atul Batra","doi":"10.1200/GO-25-00137","DOIUrl":"https://doi.org/10.1200/GO-25-00137","url":null,"abstract":"<p><strong>Purpose: </strong>Genetic predisposition plays an important role in the pathogenesis of renal cell carcinoma. The prevalence of pathogenic/likely pathogenic (P/LP) in patients with renal cell cancer (RCC) is highly variable, and close to 40% of these can be missed with the current testing guidelines.</p><p><strong>Methods: </strong>This is a prospective study of all patients with metastatic RCC unselected for high-risk features, registered at our center between September 2023 and August 2024. Baseline clinicopathologic details were collected, and germline whole-exome sequencing was done on blood samples. Our aim was to determine the frequency of germline mutations in an unselected cohort of patients with metastatic RCC. Germline P/LP variants were visualized using cBioPortal, and chi-square and Mann-Whitney <i>U</i> tests were used to identify differences in patients with/without these variants.</p><p><strong>Results: </strong>Out of 140 participants, P/LP variants in cancer-predisposition genes were detected in 20%, and 4.2% were in RCC-associated genes. <i>Fumarate hydratase</i> was the most common RCC-associated variant (2.8%), while <i>WT1</i>, <i>BRCA1</i>, <i>BRIP1,</i> and <i>ATM</i> (1.4% each) were the commonest non-RCC-associated variants. RCC-associated genes were more frequent in non-clear cell histology (<i>P</i> = .02); there was no difference in cancer predisposition genes on the basis of age, histology, or sex.</p><p><strong>Conclusion: </strong>Patients with advanced RCC have a high prevalence of germline variants in both RCC-associated and non-RCC cancer-specific genes irrespective of the high-risk genetic features, signifying the importance of a baseline genetic evaluation in all patients with advanced RCC as it has implications for family screening and, in future, selection of therapy.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500137"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144612161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing Interventional Radiology in a Low-Resource Setting: Lessons From Obafemi Awolowo University Teaching Hospitals Complex, Nigeria.","authors":"Adeleye D Omisore, Akinola A Odedeyi, Olusola C Famurewa, Adeniyi S Aderibigbe, Roli Y Akinsulore, Folasade M Adeyemi, Adebayo F Adisa, Ernestina C Orji, Abidemi I Ayeni, Anuoluwapo G Towoju, Victoria L Mango, Yolanda Bryce, Oluwatosin Z Omoyiola, Marcia Edelweiss, Farouk Dako, Olusegun I Alatise, Peter T Kingham, Elizabeth J Sutton","doi":"10.1200/GO-24-00637","DOIUrl":"10.1200/GO-24-00637","url":null,"abstract":"<p><strong>Purpose: </strong>The introduction of an interventional radiology (IR) unit at the Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC) in 2017 marked a significant advancement in health care delivery in a low-resource setting in Nigeria. This study documents the processes, milestones, services, challenges, innovations, and collaborations that have supported the establishment of an IR unit.</p><p><strong>Methods: </strong>We conducted an institutional review board-approved retrospective case study using archival data from the service records (2017-2024). To supplement our findings, we distributed a structured survey to 51 referring clinicians using Google Forms, with a 100% response rate. We analyzed the data descriptively using Microsoft Excel.</p><p><strong>Results: </strong>The establishment of the IR unit in the OAUTHC was driven by structured training, international collaborations, and innovative solutions to overcome infrastructural limitations. The unit began with breast intervention services and was expanded to offer diverse ultrasound- and computed tomography-guided body intervention services. Breast biopsies (31.4%) and liver biopsies (23.5%) constituted the majority of IR referrals. Survey respondents (78.4%; 40 of 51) acknowledged the significant impact of IR services in reducing the need for invasive surgeries, with 84.3% (43 of 51) suggesting the need for increased procedure availability to address long waiting times. Despite challenges such as limited procedural options (56.9%) and long waiting times (41.2%), clinicians rated the IR unit's contributions to patient care as very important (41.2%) or moderately important (52.9%). Key lessons include the importance of structured training programs, leveraging international partnerships to overcome resource gaps, and implementing adaptive strategies to meet local needs.</p><p><strong>Conclusion: </strong>The IR unit transformed patient care at the OAUTHC. This is a replicable model for building sustainable IR programs in other Nigerian hospitals and low-resource settings.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400637"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12312414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study.","authors":"Mimma Rizzo, Andrey Soares, Shilpa Gupta, Fabio Calabrò, Hideki Takeshita, Maria Teresa Bourlon, Se Hoon Park, Patrizia Giannatempo, Zin War Myint, Thomas Büttner, Enrique Grande, Ondrej Fiala, Daniele Santini, Aristotelis Bamias, Roubini Zakopoulou, Sebastiano Buti, Ravindran Kanesvaran, Pasquale Rescigno, Javier Molina-Cerrillo, Ilana Epstein, Fernando Sabino Marques Monteiro, Francesco Massari, Camillo Porta, Joaquin Bellmunt, Matteo Santoni","doi":"10.1200/GO-24-00564","DOIUrl":"10.1200/GO-24-00564","url":null,"abstract":"<p><strong>Purpose: </strong>Our investigation assessed the impact of geographical disparities in the treatment of patients with advanced urothelial cancer (aUC) included in the international, real-world ARON-2 trial.</p><p><strong>Patients and methods: </strong>The study population comprised 1,137 patients with aUC treated with pembrolizumab for relapsed or progressive disease after platinum-based chemotherapy (PBC) at 63 institutions in 19 countries. Patients were divided into three geographical areas: Europe (area 1: 791 patients), the United States (area 2: 156 patients), and Asia (area 3: 190 patients). Clinicopathologic and treatment data were extracted from medical records. The primary end points were to identify differences in patient and treatment characteristics and to assess overall survival (OS) and progression-free survival (PFS) between the three areas.</p><p><strong>Results: </strong>There were differences in patient characteristics: more patients age 70 years and older in area 1; more patients with BMI ≥25 kg/m², squamous histotype, and T1 neoplasia at diagnosis in area 2; and more pure urothelial carcinoma in area 3. There were differences in treatment characteristics: Bacillus Calmette-Guérin instillations and primary tumor surgery were more common in area 1; neoadjuvant and adjuvant PBC, third-line therapies, and specifically enfortumab vedotin (EV) were less common in area 1. Median OS (mOS) from pembrolizumab initiation was 13.0 months in area 1, 29.1 months in area 2 and 13.2 months in area 3 (<i>P</i> < .001), and median PFS was 4.8 months, 5.2 months, and 3.8 months, respectively (<i>P</i> = .002). In patients receiving EV after progression to PBC and pembrolizumab, mOS was 44.1 months in area 1, 31.7 months in area 2, and 23.8 months in area 3 (<i>P</i> = .267).</p><p><strong>Conclusion: </strong>Real-world data suggest that facilitating and extending access to targeted therapies for patients with aUC in different geographical areas worldwide may lead to a consistent and widespread survival increase.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400564"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Mediastinal Germ Cell Tumors: A Real-World Analysis of Clinical Characteristics, Treatment, and Survival Outcomes From Two Tertiary Cancer Centers in India.","authors":"Bharath Gangadhar, Chitrakshi Nagpal, Aparna Sharma, Bivas Biswas, Somnath Roy, Aditya Bhagwat, Deepam Pushpam, Sameer Bakhshi, Sunil Kumar, Kunhi Parambath Haresh, Atul Batra","doi":"10.1200/GO-25-00099","DOIUrl":"10.1200/GO-25-00099","url":null,"abstract":"<p><strong>Purpose: </strong>Mediastinal germ cell tumors (GCTs) are rare malignancies, predominantly affecting young males, with limited real-world data on treatment outcomes in India. This study aimed to evaluate the clinical characteristics, treatment patterns, and survival outcomes of patients with mediastinal GCTs, emphasizing the effectiveness of first-line chemotherapy regimens.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 81 patients diagnosed with mediastinal GCTs at two tertiary cancer centers in India from 2005 to 2023. Data on demographics, histological subtypes, presenting symptoms, treatment regimens, and outcomes were collected. Kaplan-Meier analysis was used to calculate progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>The median age at diagnosis was 26 years, with a male predominance (96.3%). Common histological subtypes included seminoma (34.3%) and yolk sac tumor (31.3%). First-line chemotherapy comprised bleomycin, etoposide, and cisplatin (BEP; 60.5%) and etoposide, ifosfamide, and cisplatin (VIP; 27.8%). Response rates included complete response (25.3%) and partial response (54.4%). After a median follow-up of 15 months, the median PFS and OS were not reached, with 2-year PFS and OS rates of 92.7% and 93.3%, respectively. Seminomas demonstrated better PFS compared with nonseminomatous GCTs (<i>P</i> = .004). Severe toxicities were observed in 48.1% of patients, with febrile neutropenia being the most common.</p><p><strong>Conclusion: </strong>This study highlights the effectiveness of BEP and VIP chemotherapy in achieving high response rates and favorable survival outcomes in mediastinal GCTs. Early diagnosis, appropriate histological classification, and aggressive multimodal treatment strategies are essential for improving long-term outcomes in this predominantly young patient population. Further research is warranted to validate these findings and optimize therapeutic approaches.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500099"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144612162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding the Pediatric Neuro-Oncology Teleconference Experience: From Twinning to International Cases Discussions.","authors":"Essra' Al Badarin, Omar Chamdine, Moatasem Elayadi, Abeer Al-Battashi, Mohammed Al Nuaimi, Eman Taryam Alshamsi, Laila Hessissen, Hiba Al-Tarrah, Eslam Maher, Roula Farah, Ata Maaz, Waleed Said, Ruba Hazaimeh, Maher Khader, Khadra Salami, Cynthia Hawkins, Mohamed S Abdelbaki, Ute Bartels, Uri Tabori, Eric Bouffet, Nisreen Amayiri","doi":"10.1200/GO-25-00023","DOIUrl":"https://doi.org/10.1200/GO-25-00023","url":null,"abstract":"<p><strong>Purpose: </strong>Video teleconferencing in neuro-oncology is feasible and sustainable. The well-established, 20-year long monthly teleconference between King Hussein Cancer Center (KHCC), Jordan, and SickKids, Canada, is an example. Since 2018, several regional centers joined these meetings to discuss their patients' management plans. We aim to evaluate this experience.</p><p><strong>Methods: </strong>We reviewed the minutes of 56 meetings (2018-2023). Preconference local treatment plans were compared with postconference recommendations. We documented the implementation of recommendations and the impact perceived by the treating oncologists.</p><p><strong>Results: </strong>Two hundred fifty-one patients were discussed: 137 from Jordan and 114 from eight other countries. Four of the 14 participating oncologists had formal pediatric neuro-oncology training. Of the 227 patients (90%), where the local multidisciplinary team had suggested a preconference plan, the teleconference recommendations concurred with the proposed plan in 50% of cases, agreed on it and proposed an alternative option in 18%, and disagreed in 32%. The difference in recommendations mostly affected the proposed treatment modality. In 64% of discordant plans and 50% of alternative plans, the treating team applied the recommendations. The main challenges in applying the recommendations were attributed to patient-related factors (51%), local team consensus on a different plan (26%), or logistic difficulties (23%). The high patient load, longer involvement in teleconferencing, formal neuro-oncology training, and well-established multidisciplinary team helped the KHCC team formulate more concordant plans.</p><p><strong>Conclusion: </strong>This experience illustrates the potential benefit for physicians to get an expert opinion on challenging cases. The participating oncologists valued the shared educational experience, especially those related to molecular testing and treatment implications. Joining such regional teleconferences is of particular importance to centers with small patient volume or those lacking a pediatric neuro-oncologist.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500023"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144612160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Charting Postoperative Trajectories in Patients With Cancer: Perspectives From a Resource-Constrained Setting in Northeast India.","authors":"Bhavana Kulkarni, Laxman Kumar Mahaseth, Tanu Anand, Arun Seshachalam, Surendran Veeraiah, Ritesh Tapkire, Ravi Kannan","doi":"10.1200/GO-24-00528","DOIUrl":"https://doi.org/10.1200/GO-24-00528","url":null,"abstract":"<p><strong>Purpose: </strong>Perioperative monitoring in critical care facility is a major determinant of postoperative outcome. However, critical care resources are finite and expensive. Thus, identifying those most likely to benefit is of great importance in resource-constrained settings. Hence, this study aims to identify prognostic factors predicting postoperative mortality and morbidity for patients in surgical units. This may help in identifying high-risk patients and developing an approach to reduce mortality.</p><p><strong>Methods: </strong>This was a cohort study involving secondary data of all patients with cancer age 18 years and older and admitted to the critical care. Preoperative, intraoperative, and postoperative parameters were extracted in Excel from the cloud physician electronic database. Descriptive analysis and log-binomial regression were used to analyze the data using STATA version 12. 1. Poor postoperative outcomes were defined as the occurrence of morbidity (unplanned postoperative course) or mortality.</p><p><strong>Results: </strong>The study included 421 patients with a mean age of 58.02 years (SD, 12.85). The majority of the patients were in the age range of 41-60 years (53%), 29% were older than 60 years, and 88% were found to use tobacco. Of all patients, 287 (68%) had significant postoperative morbidity and 13 patients (3%) died. Acute Physiology and Chronic Health Evaluation (APACHE-II) score >15 (adjusted relative risk [RR], 4.5 [95% CI, 1.48 to 14.01]), surgeon's experience <10 years (adjusted RR, 1.7 [95% CI, 1.06 to 2.94]), and blood loss more than 100 ml (adjusted RR, 2.42 [95% CI, 1.43 to 4.10]) were found to be significant predictors of poor postoperative outcomes.</p><p><strong>Conclusion: </strong>Higher APACHE-II scores, significant blood loss, and operated by less experienced surgeon were the major determinants of poor postoperative outcomes and necessitate postoperative monitoring in critical care facilities.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400528"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer.","authors":"Kumar Prabhash, Roshan Pawar, Vijaya Gunjal","doi":"10.1200/GO-25-00216","DOIUrl":"https://doi.org/10.1200/GO-25-00216","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500216"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}